Method for preparing and amplifying hematopoietic stem cells in vitro
By using a 3D gel culture system formed by fibrinogen and thrombin in vitro, the problem of insufficient expansion of hematopoietic stem cells is solved, and the efficient amplification and self-renewal ability of HSC cells is achieved, and the clinical application potential is significant.
Patent Information
- Application Number
- CN202411195990.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-28
- Publication Date
- 2024-11-15
AI Technical Summary
The prior art is difficult to expand and stabilize hematopoietic stem cells in vitro, which limits the clinical application of stem cell transplantation.
A 3D fibrinogen and thrombin were used to establish a 3D fibrinogen gel culture system. By mixing umbilical cord blood mononuclear cells with fibrinogen and thrombin, adding cytokines after forming a gel, large-scale amplification of HSC cells was achieved.
The long-term expansion and self-renewal ability of HSC cells has been achieved, the viability of cells and the ability to rebuild hematopoiesis in vivo, breaks through the problem of insufficient number of cells in the existing technology, and has clinical application prospects.
Smart Images

Figure HDA0005016966750000011 
Figure HDA0005016966750000012 
Figure HDA0005016966750000013
Abstract
Description
Technical Field
[0001] The present application relates to the fields of biomedicine and immunotherapy, and more specifically, to a method for preparing and amplifying hematopoietic stem cells in vitro. Background Art
[0002] Hematopoietic stem cells (HSCs) are a type of adult tissue stem cells that can produce hematopoietic progenitor cells such as lymphoid and myeloid lineages through directed differentiation, and then proliferate and differentiate into various mature functional blood cells to maintain the hematopoietic homeostasis of the whole body. HSCs have biological characteristics such as self-renewal, multilineage differentiation, apoptosis, movement and migration, and can be used to treat a variety of diseases including benign and malignant diseases of the blood system, autoimmune diseases (such as mucopolysaccharidosis type II) and solid tumors (such as neuroblastoma).
[0003] In recent years, with the continuous development of immunological technology and the characteristics of HSC supporting hematopoiesis and rebuilding the entire blood system after transplantation, stem cell gene therapy including haploid hematopoietic stem cell transplantation (haplo-HSCT) and umbilical cord blood stem cell transplantation (UCBT) has also become a mainstream research hotspot and has gradually become one of the main treatments for malignant diseases of the blood system in clinical practice. However, the insufficient number of stem cells limits the widespread application of stem cell transplantation in clinical practice. Therefore, it is urgent to solve the fundamental problem of stable culture and expansion of HSC in vitro.
[0004] At present, the method of in vitro HSC cell expansion is mainly based on cytokine induction, that is, by adding a variety of cytokines including SCF, Flt3L, G-CSF, GM-CSF, IL-3, IL-6, TPO, TNFSF15, etc., activating multiple signaling pathways including JAK-STAT, Notch, Wnt, etc., maintaining the in vivo HSC cell phenotype while inducing a large number of HSC in vitro expansion. However, the number of HSC cells cultured by this method is small, which is difficult to meet the requirements for clinical use. Summary of the invention
[0005] Human fibrinogen is a glycoprotein synthesized and secreted by liver cells. It is one of the most abundant coagulation factors in plasma. It can be converted into fibrin under the action of thrombin and form a stable, porous fibrin gel after coagulation. As an insoluble protein, fibrin can be digested and degraded by dispase. The use of a fibrin gel culture system can provide cells with a 3D culture environment, better simulate the in vivo environment, and thus provide experimental conditions closer to the physiological state, which is of great significance for studying cell behavior, cell-cell interactions, and cell-microenvironment interactions.
[0006] Without being limited to a specific theory, the technical solution of the present application is at least partially based on the discovery that applying the aforementioned 3D culture system to HSC cell culture helps to achieve large-scale expansion of HSC, especially long-term hematopoietic stem cells (LT-HSC) with high self-renewal ability and multidirectional differentiation potential, and develop more effective HSC expansion strategies.
[0007] The present application develops a method for in vitro large-scale expansion of HSC cells by using fibrinogen and thrombin to establish a 3D fibrin gel culture system. The HSC cells prepared by this method not only have the ability of in vitro large-scale expansion, self-renewal and longer-lasting survival, but also have the ability to reconstruct hematopoiesis and the potential for directional differentiation of various lineages after infusion of HSC cells in vivo.
[0008] In order to solve the problem that HSC cells cannot be prepared and expanded in large quantities in vitro, the present application is proposed.
[0009] In a first aspect, the present application provides a method for preparing and expanding hematopoietic stem cells in vitro, which comprises or consists of the following steps:
[0010] 1) Obtaining isolated umbilical cord blood-derived mononuclear cells (UBMC);
[0011] 2) mixing the separated UBMC cells, the fibrinogen solution and the thrombin solution to obtain a culture;
[0012] 3) contacting the culture with dispase and passaging the culture to obtain hematopoietic stem cells.
[0013] In some embodiments, in step 1) of the method of the present application, the umbilical cord blood mononuclear cells are isolated from the umbilical cord blood of a mammal, the mammal is a non-human mammal or a human, preferably the mammal is a human.
[0014] In some embodiments, in step 2) of the method of the present application, the isolated UBMC cells are mixed with a fibrinogen solution, seeded into a culture plate pre-incubated with a thrombin solution, incubated for 30 minutes to allow the fibrinogen to be completely converted into a fibrin gel and encapsulate the umbilical cord blood mononuclear cells, and then culture medium is added, wherein the fibrinogen is human fibrinogen and the thrombin is human thrombin.
[0015] In some embodiments, the final concentration of fibrinogen is 1-20 mg / ml, for example but not limited to 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 μg / ml, more preferably 2-5 mg / ml, and further preferably 4 mg / ml.
[0016] In some embodiments, the concentration of thrombin is 0.01-1 U / μl, for example but not limited to 0.01, 0.02, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, 0.09, 0.1, 0.15, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0 U / μl, more preferably 0.05-0.2 U / μl, and further preferably 0.1 U / μl.
[0017] In some embodiments, the culture medium added after incubation for 30 minutes is a hematopoietic stem cell culture medium containing human FLT3L recombinant protein, human TPO recombinant protein and human SCF recombinant protein.
[0018] In some embodiments, in step 3) of the method of the present application, after culturing for 4-6 days, preferably 5 days, the culture obtained in step 2) is contacted with dispase and passaged to obtain hematopoietic stem cells; preferably, the concentration of the dispase is 1-10 mg / ml, for example but not limited to 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 mg / ml, more preferably 2-5 mg / ml, further preferably 4 mg / ml; preferably, the passage is performed at least 3 times.
[0019] In a second aspect, the present application provides a kit for preparing and expanding hematopoietic stem cells in vitro, and comprising:
[0020] isolated cord blood mononuclear cells;
[0021] Fibrinogen;
[0022] Thrombin; and
[0023] Optionally, dispase.
[0024] In some embodiments, the fibrinogen is human fibrinogen and the thrombin is human thrombin.
[0025] In a further embodiment, the final concentration of the fibrinogen is 1-20 mg / ml, more preferably 2-5 mg / ml, further preferably 4 mg / ml; the concentration of the thrombin is 0.01-1 U / μl, more preferably 0.05-0.2 U / μl, further preferably 0.1 U / μl.
[0026] In a further embodiment, the concentration of the dispase is 1-10 mg / ml, preferably 2-5 mg / ml, more preferably 4 mg / ml.
[0027] In a third aspect, the present application provides the use of fibrinogen and thrombin in preparing a kit for preparing and expanding hematopoietic stem cells in vitro.
[0028] In some embodiments, the fibrinogen is human fibrinogen and the thrombin is human thrombin.
[0029] In a further embodiment, the final concentration of the fibrinogen is 1-20 mg / ml, more preferably 2-5 mg / ml, further preferably 4 mg / ml; the concentration of the thrombin is 0.01-1 U / μl, more preferably 0.05-0.2 U / μl, further preferably 0.1 U / μl.
[0030] In a fourth aspect, the present application provides hematopoietic stem cells obtained by the method or kit of the present application.
[0031] In some embodiments, the hematopoietic stem cells have one or more of the following characteristics:
[0032] 1) Added Lin - CD45RA - CD38 - CD34 + CD90 + CD49F + Long-term hematopoietic stem cell ratio;
[0033] 2) The expression levels of significantly upregulated HSC-related genes RUNX1, CD93, THY1, CD34, EPCR, ITGA3, and TAL1;
[0034] 3) In vitro multi-lineage clone formation ability;
[0035] 4) the ability to self-renew in vivo; and
[0036] 5) Efficient lineage reconstruction capability in vivo.
[0037] The applicant has found through a large number of experimental studies that HSC cells cultured in 3D fibrin gel can maintain long-term hematopoietic stem cell phenotype (Lin - CD45RA - CD38 - CD34 + CD90 + CD49F + ), and the cumulative increase of stemness phenotype is more obvious with the increase of passage number; highly express HSC-related genes (RUNX1, CD93, THY1, CD34, EPCR, ITGA3 and TAL1); have a large number of expansion capabilities in vitro; and have self-renewal ability and efficient lineage reconstruction ability in vivo. This application provides a technical solution for large-scale production and expansion of functional HSC cells.
[0038] In this application, when referring to numerical values, it should be understood that it includes appropriate error ranges, such as ±1%, ±1.5%, ±2%, ±2.5%, ±3%, ±3.5%, ±4%, ±4.5%, ±5%, ±5.5%, ±6%, ±6.5%, ±7%, ±8%, ±9%, ±10%. This is mainly due to the reasonable errors introduced by the measurement method, personnel operation, raw materials themselves, operating environment, instruments and equipment, etc. For example, due to the accuracy of the measurement method of concentration and enzyme activity, as well as the proficiency of personnel, sampling and other factors, the concentration of 100IU / ml can refer to 100IU / ml within the error range, and the technician can determine the specific error range according to the conditions of the context. When there is no clear limitation, the error range is ±10%, that is, "100IU / ml" should be understood as 90-110IU / ml.
[0039] When referring to time, it should not be understood that it is accurate to the second, but there may be errors of ±1%, ±1.5%, ±2%, ±2.5%, ±3%, ±3.5%, ±4%, ±4.5%, ±5%, ±5.5%, ±6%, ±6.5%, ±7%, ±8%, ±9%, ±10%. For example, due to the influence of human operation and timer error, there may be an error of ±10% in 5 days.
[0040] The methods of the present application are not directed to the diagnosis or treatment of disease. BRIEF DESCRIPTION OF THE DRAWINGS
[0041] Figures 1A to 1G It was shown that UBMC cells can be cultured in 3D fibrin gels and proliferate HSC cells in large quantities.
[0042] Figure 2 It showed that UBMC cells expanded in 3D fibrin gel had higher expression levels of stemness molecules.
[0043] Figure 3It was shown that UBMC cells expanded from 3D fibrin gel had multi-lineage clone-forming ability in vitro.
[0044] 4A to 4H It was shown that UBMC cells expanded from 3D fibrin gels have self-renewal ability and efficient lineage reconstruction ability in vivo. DETAILED DESCRIPTION
[0045] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this application belongs.
[0046] Various cell lines, animals, etc. used in the examples:
[0047] Human umbilical cord blood was obtained from volunteers; immunodeficient NCG mice were purchased from Jiangsu Jicui Yaokang Biotechnology Co., Ltd.
[0048] Unless otherwise specified, the raw materials and reagents used in the present invention are commercially available.
[0049] Example 1: UBMC cells can be cultured in 3D fibrin gel and a large number of HSC cells can be expanded
[0050] 1. Experimental Procedure
[0051] 3D fibrin gel HSC cell culture system:
[0052] 1) Collect human umbilical cord blood, separate UBMC cells using Ficoll reagent, and lyse red blood cells using red blood cell lysis buffer;
[0053] 2) Collect the separated UBMC cells and culture them at an initial density of 5×10 5 5×10 cells / well were inoculated into a 24-well plate to prepare a rigid plate control for culturing Fla-UBMC cells; 3.5 μL of thrombin solution (0.1 U / μL, Sea Run Holdings, Cat: SEA-135) was pre-added to the 24-well plate, and then 5×10 5The collected UBMC cells were mixed with human fibrinogen solution (RiaSTAP, Cat: NDC 63833-891-90) to a final fibrinogen concentration of 4 mg / ml (450Pa), and 250 μL of the mixture was immediately inoculated into each well of a 24-well cell culture plate and incubated in a 37°C, 5% CO2 incubator for 30 minutes to allow the fibrinogen to be completely converted into fibrin gel and wrap the UBMC cells to form a reticular structure. 1 ml of StemSpan containing cytokine human Flt-3 ligand (FLT3L) recombinant protein (PeproTech, Cat: 300-19-50UG), human thrombopoietin (TPO) recombinant protein (PeproTech, Cat: 300-18-50UG) and human stem cell factor (SCF) recombinant protein (PeproTech, Cat: 300-07-50UG) was added. TM SFEMII (STEMCELL, Cat: 09655) culture medium was added to each well and cultured continuously to prepare 3D-UBMC cells;
[0054] 3) Continue to culture Fla-UBMC cells and 3D-UBMC cells in the culture medium described in 2) above, and perform subculture on the 5th day and the 10th day according to the cell growth conditions, and change the medium every 2 days;
[0055] 4) After 15 days, the supernatant of each well was discarded, and 400 μL of dispase II (5 mg / mL, ROCHE, REF: 04942078001) was added, and the cells were incubated in a 37°C, 5% CO2 incubator until the fibrin was completely degraded and the 3D-UBMC cells encapsulated therein were released, and the Fla-UBMC cells were harvested at the same time. The total number of Fla-UBMC cells and 3D-UBMC cells was counted under a microscope using a cell counting plate;
[0056] 5) All samples were stained with Live / Dead dye at room temperature for 10 minutes, and then the HSC-related antibody CD34 was used to stain Fla-UBMC cells and 3D-UBMC cells, and the expansion times and number of CD34-positive cells were counted; long-term hematopoietic stem cell (LT-HSC) phenotype-related antibodies (Lin, CD45RA, CD38, CD34, CD90, CD49F) were used to stain, and the number of LT-HSC (Lin) was counted. - CD45RA - CD38 - CD34 + CD90 + CD49F +) The expansion times and number of positive cells. Invitrogen Attune NxT software was used for data collection and FlowJo software was used for data analysis.
[0057] 2. Experimental results
[0058] 2.1 Umbilical cord blood-derived UBMC cells have a faster proliferation rate in the 3D fibrin gel culture system (3D-UBMC) than in the rigid plate (Fla-UBMC), and the cumulative increase in proliferation rate is more obvious with the increase in the number of passages ( Figure 1A , Figure 1B ): After 15 days, umbilical cord blood-derived UBMC cells in rigid plates (Fla-UBMC) increased from an initial density of 5×10 5 The number of cells / well was expanded to 2.3×10 6 / well, while in 3D fibrin gel (3D-UBMC) the number of cells expanded to 3.6×10 6 / well, and the amplification times were 4.6 and 7.2 times respectively.
[0059] 2.2 Umbilical cord blood-derived UBMC cells have a faster CD34-positive cell proliferation rate in the 3D fibrin gel culture system (3D-UBMC) than in the rigid plate (Fla-UBMC), and the cumulative increase in CD34-positive cell proliferation rate is more obvious with the increase in the number of passages ( Figure 1C to Figure 1E ): After 15 days, the proportion of CD34-positive cells of umbilical cord blood-derived UBMC cells in rigid plates (Fla-UBMC) expanded from the initial 6% to 18%, and in 3D fibrin gels (3D-UBMC) expanded to 45%, and the number of CD34-positive cells increased from the initial 3×10 4 4.14×10 5 and 1.62×10 in the 3D-UBMC group 6 The amplification folds were 13.7 and 54, respectively.
[0060] 2.3 The UBMC cells derived from umbilical cord blood have a higher proportion of LT-HSC positive cells in the 3D fibrin gel culture system (3D-UBMC) than in the rigid plate (Fla-UBMC), and the cumulative increase in the proportion of LT-HSC positive cells is more obvious with the increase in the number of passages ( Figure 1F , Figure 1G ): The proportion of LT-HSCs in freshly isolated UBMC cells was 0.005% on day 0, which increased to 1% in 3D-UBMCs and 0.09% in Fla-UBMCs on day 15. That is, the proportion of LT-HSC cells increased by 222 times and 21 times in the 3D-UBMC and Fla-UBMC groups, respectively.
[0061] Example 2: 3D-UBMC cells have higher expression levels of HSC molecules
[0062] 1. Experimental Procedure
[0063] qPCR: 3D-UBMC cells and Fla-UBMC cells were collected, lysed with Trizol, and RNA was extracted and reverse transcribed into cDNA. qPCR was performed using the corresponding primers of HSC-related genes (RUNX1, CD93, THY1, CD34, EPCR, ITGA3, and TAL1).
[0064] 2. Experimental results
[0065] qPCR results showed that compared with Fla-UBMC cells, the mRNA levels of CD93, THY1, CD34, and EPCR in 3D-UBMC cells were significantly upregulated, and the mRNA levels of RUNX1, ITGA3, and TAL1 were slightly increased ( Figure 2 ).
[0066] Example 3: 3D-UBMC cells have multi-lineage clonal formation ability in vitro
[0067] 1. Experimental Procedure
[0068] After five days of culture, 2×103 3D-UBMC or Fla-UBMC cells were mixed with MethoCult TM The culture medium was mixed to 1.1 mL and inoculated into a 6-well plate, and cultured in a humidified incubator at 37°C and 5% CO 2 . After 14 days, the number and type of colonies were counted and analyzed.
[0069] 2. Experimental results
[0070] The number and type of colonies were counted and analyzed, and it was found that the number of CFU in 3D-UBMC cells increased significantly, including burst-forming units-erythroid (BFU-E), CFU-granulocyte / macrophage (CFU-GM), and CFU-granulocyte / erythrocyte / macrophage / megakaryocyte (CFU-GEMM), which were 53, 31, and 10, respectively. In contrast, the Fla-UBMC group had a weaker ability to generate CFU, with the numbers of BFU-E, CFU-GM, and CFU-GEMM being 42, 17, and 2, respectively. Figure 3 ).
[0071] Example 4: 3D-UBMC cells have self-renewal and efficient lineage reconstruction capabilities in vivo
[0072] 1. Experimental Procedure
[0073] 1.1 Primary transplantation assay: Immunodeficient NCG mice were irradiated with a dose of 1.5 Gray in advance, and then human 3D-UBMC and Fla-UBMC cells cultured on 3D fibrin gel and rigid plates for 14 days were collected and transplanted at a rate of 5 × 10 per mouse. 5 The dose of each cell was adopted into the irradiated mice by tail vein. The mice were killed 16 weeks later, and the peripheral blood, bone marrow, and spleen of each mouse were collected, and single cell suspensions were prepared. The proportion of human HSC cells in the above cells in each group was stained with hCD45 and CD34 antibodies and analyzed; the proportion of human myeloid cells in the above cells in each group was stained with hCD45 and CD15 antibodies and analyzed; the proportion of human B cells in the above cells in each group was stained with hCD45 and CD19 antibodies and analyzed; the proportion of human T cells in the above cells in each group was stained with hCD45 and CD3 antibodies and analyzed. Invitrogen Attune NxT software was used for data collection, and FlowJo software was used for data analysis.
[0074] 1.2 Secondary transplantation assay: Bone marrow was isolated from 3D-UBMC group and Fla-UBMC group mice 16 weeks after primary transplantation, with 1×10 6 The dose of each cell was adopted into a new batch of NCG mice irradiated with a dose of 1.5Gray by tail vein for secondary transplantation assay. The mice were killed 16 weeks later, and the peripheral blood, bone marrow, and spleen of each mouse were collected, and single cell suspensions were prepared. The proportion of human HSC cells in the above cells in each group was stained with hCD45 and CD34 antibodies and analyzed; the proportion of human myeloid cells in the above cells in each group was stained with hCD45 and CD15 antibodies and analyzed; the proportion of human B cells in the above cells in each group was stained with hCD45 and CD19 antibodies and analyzed; the proportion of human T cells in the above cells in each group was stained with hCD45 and CD3 antibodies and analyzed. Invitrogen Attune NxT software was used for data collection, and FlowJo software was used for data analysis.
[0075] 2. Experimental results
[0076] The proportion of each cell type in the peripheral blood, bone marrow, and spleen of mice after adoptive 3D-UBMC and Fla-UBMC was analyzed by flow cytometry. Figure 4A-4D ) and secondary transplantation ( Figure 4E-4H ), the proportion of human HSC cells, myeloid cells, and lymphocytes (T cells and B cells) in the adoptive 3D-UBMC cell group was significantly higher than that in the adoptive Fla-UBMC group, and the proportion of each type of cells after the second transplantation was significantly higher than that in each group after the first transplantation.
[0077] In summary, the solution of this application has the following effects:
[0078] 1. The present application uses fibrinogen and thrombin to form a 3D fibrin gel culture system, which can prepare and expand HSC cells on a large scale, and has the characteristics of high expansion efficiency, low degree of differentiation, and the ability to self-renew.
[0079] 2. The HSC cells prepared by the method and kit of the present application have a higher expression level of stemness genes and expression levels of transcription factors related to maintaining HSC self-renewal.
[0080] 3. The method and kit of the present application can generate a large number of LT-HSC cell populations, which can be directed to differentiate into cells of various lineages and reconstruct hematopoiesis in vivo, and the generated mature cells have extremely strong biological power, so as to break through the limitations of existing hematopoietic stem cell transplantation and have great clinical application prospects.
Claims
1. A method for preparing and expanding hematopoietic stem cells in vitro, comprising: 1) obtaining isolated umbilical cord blood mononuclear cells; 2) mixing the separated umbilical cord blood mononuclear cells, the fibrinogen solution and the thrombin solution to obtain a culture; 3) contacting the culture with dispase and passaging the culture to obtain hematopoietic stem cells.
2. The method according to claim 1, wherein: In step 1), the umbilical cord blood mononuclear cells are isolated from the umbilical cord blood of a mammal, which is a non-human mammal or a human, and preferably the mammal is a human.
3. The method according to claim 1, wherein: In step 2), the separated umbilical cord blood mononuclear cells are mixed with a fibrinogen solution, inoculated into a culture plate pre-incubated with a thrombin solution, and incubated for 30 minutes to allow the fibrinogen to be completely converted into a fibrin gel and encapsulate the umbilical cord blood mononuclear cells, and then the culture medium is added.
4. The method according to claim 3, wherein: The fibrinogen is human fibrinogen, and the thrombin is human thrombin; Preferably, the final concentration of fibrinogen is 1-20 mg / ml, more preferably 2-5 mg / ml, further preferably 4 mg / ml±10%; Preferably, the final concentration of thrombin is 0.01-1 U / μl, more preferably 0.05-0.2 U / μl, further preferably 0.1 U / μl±10%; Preferably, the culture medium added after incubation for 30 minutes is a hematopoietic stem cell culture medium containing human Flt-3 ligand recombinant protein, human thrombopoietin recombinant protein and human stem cell factor recombinant protein.
5. The method according to claim 1, wherein: In step 3), after culturing for 4 to 6 days, preferably 5 days, the culture obtained in step 2) is contacted with dispase and passaged. Preferably, the final concentration of the dispase is 1-10 mg / ml, more preferably 2-5 mg / ml, further preferably 4 mg / ml±10%; Preferably, the passaging is performed at least 3 times.
6. A kit for preparing and expanding hematopoietic stem cells in vitro, comprising: isolated cord blood mononuclear cells; Fibrinogen; Thrombin; and Optionally, dispase.
7. The kit according to claim 6, wherein: The fibrinogen is human fibrinogen, and the thrombin is human thrombin; Preferably, the final concentration of fibrinogen is 1-20 mg / ml, more preferably 2-5 mg / ml, further preferably 4 mg / ml±10%; Preferably, the concentration of thrombin is 0.01-1 U / μl, more preferably 0.05-0.2 U / μl, further preferably 0.1 U / μl±10%; Preferably, the final concentration of the dispase is 1-10 mg / ml, more preferably 2-5 mg / ml, further preferably 4 mg / ml±10%.
8. Use of fibrinogen and thrombin in the preparation of a kit for in vitro preparation and expansion of hematopoietic stem cells, wherein: The fibrinogen is human fibrinogen, and the thrombin is human thrombin; Preferably, the final concentration of fibrinogen is 1-20 mg / ml, more preferably 2-5 mg / ml, further preferably 4 mg / ml±10%; Preferably, the concentration of thrombin is 0.01-1 U / μl, more preferably 0.05-0.2 U / μl, further preferably 0.1 U / μl±10%.
9. A hematopoietic stem cell obtained by the method according to any one of claims 1 to 5 or the kit according to claim 6 or 7, and having one or more of the following characteristics: 1) Added Lin - CD45RA - CD38 - CD34 + CD90 + CD49F + Long-term hematopoietic stem cell ratio; 2) The expression levels of significantly upregulated HSC-related genes RUNX1, CD93, THY1, CD34, EPCR, ITGA3, and TAL1; 3) In vitro multi-lineage clone formation ability; 4) the ability to self-renew in vivo; and 5) Efficient lineage reconstruction capability in vivo.
Citation Information
Cited By
Method for in-vitro preparation and expansion of hematopoietic stem cells
WO2026045816A1
